Global Oncology Market to 2023 - Robust Growth Driven by Rising Prevalence and Increased Uptake of Immune Checkpoint Inhibitors

  • ID: 4333283
  • Report
  • Region: Global
  • 420 Pages
  • GBI Research
1 of 5
Global Revenue for the Oncology Market is Forecast to Grow at a CAGR of 10.66%, from $118.6 Billion in 2016 to $241.0 Billion in 2023

FEATURED COMPANIES

  • AstraZeneca
  • Bristol-Myers Squibb
  • Celgene
  • Novartis
  • Pfizer
  • Roche
  • MORE

"Global Oncology Market to 2023 Robust Growth Driven by Rising Prevalence and Increased Uptake of Immune Checkpoint Inhibitors"

Summary:

Oncology comprises a large and diverse group of indications, encompassing virtually all sites and tissues in the human body. The diseases are characterized by abnormal cell proliferation, which is followed by local tissue invasion and, at an advanced stage of the disease, the migration of the cancer cells to other parts of the body. Cancer is a genetically driven disease, with iterative mutations providing selective advantages to the cells in the context of the specific tissue site, followed by clonal expansion.

Cancer is anticipated to become increasingly prevalent due to aging populations and rising levels of obesity in the developed world. Furthermore, the development and approval of more targeted oncology treatments is anticipated to decrease toxicity and increase chemotherapy usage in elderly patients. Targeted treatment administration will increase the overall survival of poor-performance-status patients (having impaired functional status) and enable more rounds of chemotherapy to be administered.

In 2012, there were 32.6 Million people living with any type of cancer within five years of diagnosis. These are generally incurable once they progress to the stage where they are unresectable. Chemotherapy compounds are a mainstay treatment for cancers of all types, at various disease stages. In a typical course of therapy for cancer, multiple chemotherapy compounds are administered sequentially in combination regimens, as an adjunct to surgery and radiation therapy. Chemotherapy drugs are cytotoxic to dividing cells, meaning that they act on both healthy and malignant tissues and are fairly toxic.

There has been a shift towards developing targeted therapies, such as mAbs and cell therapies. Targeted therapies, by their nature, have less toxicity associated with their use and as a result can be administered to more cancer patients, who are commonly elderly and have co-morbidities, therefore increasing the overall survival of this group and the number of treatment cycles they may receive. The most commercially successful oncology treatments are mAbs such as MabThera/Rituxan, Avastin and Herceptin.

Key market players (as determined by the total oncology revenue), namely Roche, Celgene, Bristol Myers Squibbs and Novartis, are forecast to maintain their strong market shares throughout the forecast period. Nevertheless, despite the approaching patent expiries of Avastin, Kadcyla, Perjeta and Tarceva, Roche is expected to maintain the highest market share of any company.

The report “Global Oncology Market to 2023 Robust Growth Driven by Rising Prevalence and Increased Uptake of Immune Checkpoint Inhibitors” provides an introduction to oncology, including disease epidemiology, symptoms, etiology, pathophysiology, co-morbidities and complications and prognosis. Methods of diagnosis are also provided.

In particular, this report provides the following analysis:

  • Provides an overview of the oncology marketed products landscape, including product profiles of key marketed products and revenue projections for each of these drugs.
  • Analyzes the oncology pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target, plus an analysis of the key indications in the pipeline: breast, colorectal, lung and prostate cancer. The clinical trial landscape is also examined, with an emphasis on trends in clinical trial failure rates, duration and size.
  • Presents forecast projections to 2023 on a global level, with forecasts provided for the US, plus aggregate revenue forecasts of the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan.
  • Assesses the company landscape in oncology, with an analysis of the key players, the types of company involved in this therapy area, and whether this therapy area comprises a large proportion of each company’s pipeline portfolio and total revenue.
  • Analyzes trends in co-development and licensing deals relating to oncology products. Some of the most prominent deals are discussed in detail.

Scope:

  • Global revenue for the oncology market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 10.66%, from $118.6 billion in 2016 to $241.0 billion in 2023. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
  • The oncology pipeline is large and fairly diverse and contains 7,773 products. How does the composition of the pipeline compare with that of the existing market? What are the most popular types of molecule type and molecular target in the pipeline?
  • What mechanisms of action and molecule types are most common for pipeline products being trialed in the various key indications?
  • How will the market shares and CAGRs of the top 20 pharma companies compare within oncology?
  • What proportion of the key players’ revenues will be attributable to oncology products?

Reasons to buy:

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis
  • Visualize the composition of the oncology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
  • Analyze the oncology pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
  • Understand the growth in patient epidemiology and market revenue for the oncology market globally and across the key players and product types
  • Stratify the market in terms of the generic and premium product revenue split between oncology products and assess the role of these product types in the treatment of the various cancers
  • Identify commercial opportunities in the oncology deals landscape by analyzing trends in licensing and co-development deals"
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AstraZeneca
  • Bristol-Myers Squibb
  • Celgene
  • Novartis
  • Pfizer
  • Roche
  • MORE

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Therapy Area Introduction
2.2 Symptoms
2.3 Diagnosis
2.4 Etiology and Pathophysiology
2.4.1 Etiology
2.4.2 Pathophysiology
2.5 Co-morbidities and Complications
2.6 Epidemiology Patterns - Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates
2.6.1 Breast Cancer
2.6.2 Colorectal Cancer
2.6.3 Lung Cancer
2.6.4 Prostate Cancer
2.6.5 Hematological Cancers
2.7 Prognosis
2.7.1 Breast Cancer
2.7.2 Colorectal Cancer
2.7.3 Non-Small-Cell Lung Cancer
2.7.4 Prostate Cancer
2.8 Treatment
2.8.1 Surgery and Radiation Therapy
2.8.2 Chemotherapy
2.8.3 Hormonal Therapies
2.8.4 Targeted Therapies

3 Key Marketed Products
3.1 Overview
3.2 MabThera/Rituxan (rituximab)
3.3 Avastin (bevacizumab)
3.4 Herceptin (trastuzumab)
3.5 Revlimid (lenalidomide)
3.6 Opdivo (nivolumab)
3.7 Xtandi (enzalutamide)
3.8 Gleevec/Glivec (imatinib mesylate)
3.9 Alimta (pemetrexed)
3.10 Zytiga (abiraterone acetate)
3.11 Conclusion

4 Pipeline Landscape Assessment
4.1 Overview
4.2 Pipeline Development Landscape
4.3 Molecular Targets in the Pipeline
4.4 Clinical Trials
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.2 Clinical Trial Size and Duration by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.3 Clinical Trial Size and Duration by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.5 Conclusion
4.5 Assessment of Key Pipeline Products
4.5.1 Durvalumab - AstraZeneca
4.5.2 Durvalumab and Tremelimumab - AstraZeneca
4.5.3 Abemaciclib - Eli Lilly
4.5.4 Rova-T (rovalpituzumab tesirine) - AbbVie
4.5.5 Neratinib - Puma Biotechnology
4.5.6 Acalabrutinib - AstraZeneca
4.5.7 KTE-C19 (Axicabtagene Ciloleucel) - Kite Pharma
4.5.8 Tisagenlecleucel-T - Novartis
4.5.9 Conclusion

5 Multi-scenario Market Forecast to 2023
5.1 Overall Market Size
5.2 Generic Penetration
5.3 Revenue Forecast by Molecular Target
5.3.1 Programmed Cell Death Protein 1/Programmed Cell Death 1 Ligand 1
5.3.2 Tumor Necrosis Factor
5.3.3 Tyrosine-Protein Kinase BTK
5.3.4 Cyclin-Dependent Kinases
5.3.5 Androgen Receptor
5.3.6 Vascular Endothelial Growth Factor

6 Company Analysis and Positioning
6.1 Revenue and Market Share Analysis by Company
6.1.1 Roche - To What Extent Will Newly Approved and Pipeline Product Approvals Offset the Patent Expiries of Avastin and Herceptin?
6.1.2 Celgene - How Will Multiple Patent Expiries Affect Oncology-Related Revenues?
6.1.3 Novartis - How Will Mekinist plus Tafinlar and Tasigna Perform over the Forecast Period?
6.1.4 Bristol-Myers Squibb - How Successful Will Recent Approvals Opdivo and Empliciti Become?
6.1.5 Pfizer - What Do Sutent and Inlyta Patent Expiries Mean for Pfizer?
6.1.6 AstraZeneca - How Will its Immune Checkpoint Inhibitors Durvalumab and Tremelimumab Perform?
6.2 Company Landscape
6.3 Marketed and Pipeline Portfolio Analysis

7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deals by Region, Year and Value
7.1.2 Deals by Stage of Development and Value
7.1.3 Deals by Molecule Type, Mechanism of Action and Value
7.1.4 Table for Licensing Deals Valued Above $100m
7.2 Co-development Deals
7.2.1 Deals by Region, Year and Value
7.2.2 Deals by Stage of Development and Value
7.2.3 Deals by Molecule Type, Mechanism of Action and Value
7.2.4 Table for Co-development Deals Valued $1 billion and Above

8 Appendix
8.1 References
8.2 Abbreviations
8.3 Methodology
8.3.1 Secondary Research
8.3.2 Market Size and Revenue Forecasts
8.3.3 Pipeline Analysis
8.3.4 Competitive Landscape
8.4 Contact Us
8.5 Disclaimer

1.1 List of Tables
Table 1: Oncology, Global, Symptoms of Key Indication Cancers, 2017
Table 2: Complications Associated with Breast, Colorectal, Lung, Prostate and Hematological Cancers
Table 3: Oncology, Global, Epidemiology of Key Indication Cancers, 2017
Table 4: Oncology Market, US, Breast Cancer Stage at Diagnosis and Five-Year Relative Survival (%), 2017
Table 5: Oncology Market, US, Colorectal Cancer Stage and Survival Rates (%), 2017
Table 6: Oncology Market, US, Lung Cancer Stage at Diagnosis and Five-Year Relative Survival (%), 2017
Table 7: Oncology, US, Prostate Cancer Stage at Diagnosis and Five-Year Relative Survival (%), 2017
Table 8: Optimal and Actual Chemotherapy Usage Rates, 2010
Table 9: Oncology Therapeutics Market, Global, Approved Indications for Rituxan, 2017
Table 10: Oncology Therapeutics Market, Global, Approved Indications for Avastin, 2017
Table 11: Oncology Therapeutics Market, Global, Approved Indications for Herceptin, 2017
Table 12: Oncology Therapeutics Market, Global, Approved Indications for Revlimid, 2017
Table 13: Oncology Therapeutics Market, Global, Approved Indications for Opdivo, 2017
Table 14: Oncology Therapeutics Market, Global, Approved Indications for Xtandi, 2017
Table 15: Oncology Therapeutics Market, Global, Approved Indications for Gleevec, 2017
Table 16: Oncology Therapeutics Market, Global, Approved Indications for Alimta, 2017
Table 17: Oncology Therapeutics Market, Global, Approved Indications for Zytiga, 2017
Table 18: Oncology, Global, Market Size ($bn), 2016-2023 (Part 1)
Table 19: Oncology, Global, Market Size ($bn), 2016-2023 (Part 2)
Table 20: Oncology, Global, Usage of Generics Across Key Indications, 2017
Table 21: Oncology Therapeutics Market, Global, Forecast Revenues by Company, 2016-2023
Table 22: Oncology, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006-2017
Table 23: Oncology, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006-2017
Table 24: Oncology, Global, All Pipeline Products, 2017
Table 25: Abbreviations

1.2 List of Figures
Figure 1: Oncology, Major Markets, Treatment Usage Patterns for Breast Cancer, Patients (millions), 2016-2022
Figure 2: Oncology, Major Markets, Treatment Usage Patterns for Colorectal Cancer, Patients (‘000), 2016-2023
Figure 3: Oncology, Major Markets, Treatment Usage Patterns for Lung Cancer, Patients (‘000), 2016-2023
Figure 4: Oncology, Major Markets, Treatment Usage Patterns for Prostate Cancer, Patients (millions), 2016-2021
Figure 5: Oncology, Major Markets, Treatment Usage Patterns for Hematological Cancer, Patients (‘000), 2016-2023
Figure 6: Oncology, Global, Key Marketed Products and Approved Indications, 2017
Figure 7: Oncology, Global, Annual Revenue for Rituxan ($bn), 2006-2023
Figure 8: Oncology, Global, Annual Revenues for Avastin ($bn), 2006-2023
Figure 9: Oncology, Global, Annual Revenues for Herceptin ($bn), 2006-2023
Figure 10: Oncology, Global, Annual Revenue for Revlimid ($bn), 2006-2023
Figure 11: Oncology, Global, Annual Revenues for Opdivo ($bn), 2014-2023
Figure 12: Oncology, Global, Annual Revenues for Xtandi ($bn), 2012-2023
Figure 13: Oncology, Global, Annual Revenues for Gleevec ($bn), 2006-2023
Figure 14: Oncology, Global, Annual Revenues for Alimta ($bn), 2006-2023
Figure 15: Oncology, Global, Annual Revenues for Zytiga ($bn), 2011-2023
Figure 16: Oncology, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017
Figure 17: Oncology, Global, Pipeline for Oncology by Stage of Development, Molecule Type and Program Type, 2017
Figure 18: Oncology, Global, Pipeline for Key Oncology Indications by Stage of Development, 2017
Figure 19: Oncology, Global, Pipeline for Key Oncology Indications by Molecule Type, 2017
Figure 20: Oncology, Global, Pipeline for Oncology by Molecular Target, 2017
Figure 21: Oncology, Pipeline by Mechanism of Action and Stage of Development, 2017
Figure 22: Oncology, Global, Pipeline for Key Oncology Indications by Molecular Target, 2017
Figure 23: Oncology, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2017
Figure 24: Oncology, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2017
Figure 25: Oncology, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2017
Figure 26: Oncology, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2017
Figure 27: Oncology, Global, Clinical Trial Duration by Stage of Development (months), 2006-2017
Figure 28: Oncology, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2017
Figure 29: Oncology, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2017
Figure 30: Oncology, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2017
Figure 31: Oncology, Global, Clinical Trial Size by Stage of Development (participants), 2006-2017
Figure 32: Oncology, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2017
Figure 33: Oncology, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2017
Figure 34: Oncology, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2017
Figure 35: Oncology, Global, Clinical Program Size by Stage of Development (participants), 2006-2017
Figure 36: Oncology, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2017
Figure 37: Oncology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2017
Figure 38: Oncology, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2017
Figure 39: Oncology, Global, Revenue Forecast for Durvalumab ($bn), 2017-2023
Figure 40: Oncology, Global, Revenue Forecast for Durvalumab + Tremelimumab ($bn), 2017-2023
Figure 41: Oncology, Global, Revenue Forecast for Abemaciclib ($bn), 2018-2023
Figure 42: Oncology, Global, Revenue Forecast for Rova-T ($bn), 2018-2023
Figure 43: Oncology, Global, Revenue Forecast for Neratinib ($bn), 2016-2023
Figure 44: Oncology, Global, Revenue Forecast for Acalabrutinib ($bn), 2018-2023
Figure 45: Oncology, Global, Revenue Forecast for Axicabtagene Ciloleucel ($bn), 2017-2023
Figure 46: Oncology, Global, Revenue Forecast for Tisagenlecleucel-T ($bn), 2017-2023
Figure 47: Oncology, Global, Market Size ($bn), 2016-2023
Figure 48: Oncology, Global, Generic Penetration for Annual Revenue Forecasts ($bn), 2016-2023
Figure 49: Oncology, Global, Annual Revenue Forecast for Programmed Cell Death Protein 1/ Programmed Cell Death 1 Ligand 1 ($bn), 2016-2023
Figure 50: Oncology, Global, Annual Revenue Forecast for Tumor Necrosis Factor ($bn), 2016-2023
Figure 51: Oncology, Global, Annual Revenue Forecast for Tyrosine-Protein Kinase BTK ($bn), 2016-2023
Figure 52: Oncology, Global, Annual Revenue Forecast for Cyclin-Dependent Kinases ($bn), 2016-2023
Figure 53: Oncology, Global, Annual Revenue Forecast for Androgen Receptor ($bn), 2016-2023
Figure 54: Oncology, Global, Annual Revenue Forecast for Vascular Endothelial Growth Factor ($bn), 2016-2023
Figure 55: Oncology, Global, Companies by Type, Cluster by Growth and Market Share, 2016-2023
Figure 56: Oncology, Global, Company Analysis Matrix, 2017
Figure 57: Oncology, Global, Forecast Market Share by Company (%), 2016-2023
Figure 58: Oncology, Global, Companies by Compound Annual Growth Rate (%), 2016-2023
Figure 59: Oncology, Global, Revenues by Product Type, 2016-2023
Figure 60: Oncology, Global, Roche Oncology Annual Revenue Forecast ($bn), 2016-2023
Figure 61: Oncology, Global, Celgene Annual Revenue Forecast ($bn), 2016-2023
Figure 62: Oncology, Global, Novartis AG Annual Revenue Forecast ($bn), 2016-2023
Figure 63: Oncology, Global, Bristol-Myers Annual Revenue Forecast ($bn), 2016-2023
Figure 64: Oncology, Global, Pfizer Annual Revenue Forecast ($bn), 2016-2023
Figure 65: Oncology, AstraZeneca Annual Revenue Forecast ($bn), 2016-2023
Figure 66: Oncology, Global, Companies by Type, 2016-2023
Figure 67: Oncology, Global, Pipeline, High-Activity and Late-Stage Developers by Level of Oncology Specialization, 2016-2023
Figure 68: Oncology, Global, Proportion of Total Company Revenue Attributed to Cancer, 2016-2023
Figure 69: Oncology, Global, Licensing Deals, 2006-2017
Figure 70: Oncology, Global, Licensing Deals by Indication and Value, 2006-2017
Figure 71: Oncology, Global, Licensing Deals by Volume and Value, 2006-2017
Figure 72: Oncology, Global, Licensing Deals by Molecule Type and Molecular Target, 2006-2017
Figure 73: Oncology, Global, Co-development Deals, 2006-2017
Figure 74: Oncology, Global, Co-development Deals by Indication and Value, 2006-2017
Figure 75: Oncology, Global, Co-development Deals by Volume and Value, 2006-2017
Figure 76: Oncology, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006-2017

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AstraZeneca
  • Bristol-Myers Squibb
  • Celgene
  • Novartis
  • Pfizer
  • Roche
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll